Last updated: July 30, 2025
Introduction
Brazilian patent BR112013010524, granted in 2013, pertains to a pharmaceutical composition or process involving a novel drug entity or a specific formulation. Understanding its scope, claims, and the patent landscape is critical for stakeholders including pharmaceutical companies, legal practitioners, and R&D entities aiming to navigate the intellectual property environment in Brazil.
This analysis explores the patent's core claims, scope, relevant overlaps, existing prior art, and its strategic positioning within the broader pharmaceutical patent landscape in Brazil.
Patent Overview and Filing Details
Patent BR112013010524 was filed on May 22, 2013, and granted on August 27, 2019, by the Brazilian National Institute of Industrial Property (INPI). The patent's priority date stems from a PCT application published in 2012, indicating an origin in an international application.
The patent pertains to a pharmaceutical composition or process involving specific active ingredients or delivery systems designed to improve therapeutic outcomes or bioavailability.
Scope and Claims Analysis
Claim Structure and Core Subject Matter
The patent’s claims revolve around the following key aspects:
- Pharmaceutical Composition: A combination of active pharmaceutical ingredients (APIs), possibly involving a novel ratio or formulation to enhance efficacy or stability.
- Preparation Method: Specific processes for preparing the composition, emphasizing steps that confer unique properties.
- Delivery System or Formulation: Innovative formulations such as sustained-release matrices, nano-carriers, or other drug delivery mechanisms.
In particular, the claims are structured to protect:
- Core pharmaceutical compounds or their derivatives.
- Specific ratios or combinations that result in synergistic pharmacological effects.
- Unique processing steps or formulation techniques to improve drug stability, bioavailability, or patient compliance.
Claim Types and Their Implications
The patent includes:
- Independent Claims: Covering broad compositions or methods—aiming for extensive scope within the pharmaceutical space.
- Dependent Claims: Refinements or specific embodiments—such as particular salts, dosage forms, or excipient combinations.
A noteworthy issue is that some claims possibly have limited scope, focusing narrowly on specific compounds or methods, which might leave room for designing around.
Scope Limitations and Potential Challenges
The patent claims face potential limitations:
- Prior Art Overlap: Similar known formulations or manufacturing methods in existing literature or previous patents could challenge the novelty or inventive step.
- Scope Breadth: Overly broad claims may be susceptible to invalidity if prior art can be cited against them.
- Patent Thickets: The existence of overlapping patents in Brazil related to drug delivery systems suggests a crowded patent landscape, possibly leading to infringement or licensing issues.
Patent Landscape in Brazil for Pharmaceutical Patents (Post-2010)
Brazil's patent environment for pharmaceuticals has seen significant growth, influenced by integration into global systems like the Patent Cooperation Treaty (PCT) and regional agreements.
Key observations include:
- Increase in patent filings related to drug formulations, delivery systems, and APIs.
- Prevalence of method-of-use and formulation claims, aligning with the scope seen in BR112013010524.
- Challenges to patentability especially concerning novelty and inventive step, given Brazilian patent laws' adherence to strict criteria.
Several other patents in Brazil share structural similarities with BR112013010524, often relating to extended-release formulations, combination therapies, and improved bioavailability techniques.
Legal and Strategic Positioning
Given the patent's granted status, the following considerations apply:
- Enforcement: The patent affords exclusive rights in Brazil until 2033, protecting the designated formulations/methods.
- Infringement Risks: Companies developing similar formulations must analyze claim scope carefully, especially dependent claims.
- Freedom-to-Operate (FTO): Due to complex overlaps, comprehensive FTO analyses should investigate related patents and potential licensing.
Future Outlook and Strategic Recommendations
- Monitoring Patent Remainders and Competitors: Continuous surveillance of new filings in Brazil to identify potential patent thickets.
- Claim Reassessment and Potential Challenges: Evaluating grounds for oppositions or reexaminations, especially if prior art surfaces that challenge scope.
- Innovative R&D Directions: Building on claims to develop novel formulations or methods that avoid existing IP boundaries.
Key Takeaways
- BR112013010524 covers specific pharmaceutical compositions and preparation methods, with claims tailored to particular formulations or delivery systems.
- While granting exclusive rights, the patent’s scope is somewhat narrow, necessitating careful analysis for potential design-around strategies.
- The Brazilian patent landscape remains active, especially in modified-release formulations and combination therapies, increasing the importance of diligent IP management.
- Legal challenges through prior art or invalidity proceedings could arise, positioning patent maintenance and enforcement as strategic priorities.
- Innovation beyond the patent scope, such as alternative drug delivery techniques or APIs, remains critical for competitive advantage.
FAQs
1. Can this patent be licensed or sold in Brazil?
Yes. As a granted patent, BR112013010524 can be licensed or assigned. Licensing negotiations must consider the patent’s scope and validity.
2. How does Brazilian patent law affect pharmaceutical patents like BR112013010524?
Brazilian law emphasizes novelty, inventive step, and industrial application. Pharmaceutics patents face rigorous scrutiny, especially for obviousness and prior art. Enforcement requires careful legal process.
3. Are there similar patents in Brazil that might impact the scope of BR112013010524?
Yes. The landscape includes patents on drug formulations, delivery systems, and APIs; competitors should conduct thorough patent landscaping to identify overlaps.
4. What strategies can extend the patent life beyond 2033?
While the term is generally 20 years from filing, patent term extensions or new patents on improvements/patentable modifications can reinforce IP protection.
5. How can companies avoid infringement of BR112013010524?
By analyzing the specific claims, particularly independent claims, and designing around them—such as using different active ingredients or alternative delivery mechanisms.
References
[1] Brazilian Patent Database (INPI): Patent BR112013010524.
[2] World Intellectual Property Organization (WIPO) Patentscope.
[3] Brazilian Law No. 9,279/1996—Industrial Property Law.
[4] Patent landscape reports on Brazilian pharmaceutical innovations.
[5] Case law and legal analyses from INPI patent examination records.
In conclusion, Patent BR112013010524 provides a strategic IP asset within Brazil's pharmaceutical sector. Its detailed claims and scope necessitate precise navigation for licensing, R&D, and legal challenges, amid a dynamic patent landscape emphasizing innovation in drug formulations and delivery systems.
